Clinical Trial Detail

NCT ID NCT03262779
Title Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Yale University
Indications

lung non-small cell carcinoma

Therapies

Ipilimumab + Nivolumab

Age Groups: senior adult

No variant requirements are available.